十一月 2025
- Home
- Mersana Therapeutics, Inc.
十一月 2025的Mersana Therapeutics, Inc.市场份额分析
The development of ADCs is not a one-size-fits-all approach. In fact, a number of diverse factors impact the properties of an ADC, including payload, drug-to-antibody ratio, site of conjugation and homogeneity. For each target antigen, there is an optimal combination of these factors. Our novel and highly differentiated platforms have allowed us to optimize these properties […]
Mersana Therapeutics, Inc.(包含公司地区分支机构)
查看更多网站流量和参与度信息- mersana.com
Mersana Therapeutics, Inc.收入截至 十一月 2025为 25M - 50M
Mersana Therapeutics, Inc.主要域名产生的收入
3 年中Mersana Therapeutics, Inc.主要域名的收入
Mersana Therapeutics, Inc.主要域名的收入
Mersana Therapeutics, Inc.热门域名的总访问量
了解Mersana Therapeutics, Inc.市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Mersana Therapeutics, Inc.热门域名的平均访问时长
分析Mersana Therapeutics, Inc.参与度指标。
过去 3 个月的平均访问时长
子公司明细
Mersana Therapeutics, Inc.热门域名的平均页面浏览量
了解Mersana Therapeutics, Inc.如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Mersana Therapeutics, Inc. 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Day One Biopharmaceuticals, Inc. is planning to acquire Mersana Therapeutics, Inc. for $285M.Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) has announced a definitive merger agreement to acquire Mersana Therapeutics in a deal valued at up to $285 million, marking a major expansion of its oncology portfolio.
十一月 13, 2025阅读更多
新闻Day One Biopharmaceuticals, Inc. is planning to acquire Mersana Therapeutics, Inc. for $285M.Day One Biopharmaceuticals moves to acquire Mersana Therapeutics in $285m cancer-drug deal.
十一月 13, 2025阅读更多
新闻Mersana Therapeutics, Inc. attends event ASCO 2025 Annual Meeting.Mersana Therapeutics announces upcoming Emi-Le oral and poster presentations at ASCO 2025 Annual Meeting.
四月 23, 2025阅读更多
查看 Mersana Therapeutics, Inc. 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。